Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 9, 2004 - Issue 2
Submit an article Journal homepage
67
Views
10
CrossRef citations to date
0
Altmetric
Review

Use of cytokines in infection

Naoko Aoki McMaster University, Department of Pathology and Molecular Medicine, Infectious Diseases Division, Centre for Gene Therapeutics, Rm. 4012 - MDCL, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
&
Zhou Xing McMaster University, Department of Pathology and Molecular Medicine, Infectious Diseases Division, Centre for Gene Therapeutics, Rm. 4012 - MDCL, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5. [email protected]
Pages 223-236 | Published online: 24 Feb 2005

Bibliography

  • XING Z, WANG J: Consideration of cytokines as therapeutics agents or targets. Curr. Pharm. Des. (2000) 6(6):599–611.
  • •A well-organised review about the use of cytokines as therapeutics.
  • DAVIES PD, YEW WW: Recent developments in the treatment of tuberculosis. Expert Opin. Investig. Drugs (2003) 12(8):1297–1312.
  • MATSUSHITA S, KIMURA T: Advance intreatment strategy and immune reconstruction against HIV-1 infection. Microbial. Immunol (2002) 46(4):231–239.
  • RIEDEMANN NC, GUO RF, WARD PA: The enigma of sepsis. J. Clin. Invest. (2003) 112(4):460–467.
  • PAPPAS PG: Immunotherapy for invasive fungal infections: from bench to bedside. Drug Resist. Updates (2004) 7(1):3–10.
  • YAZDANBAKHSH M, KREMSNER PG, VAN REE R: Allergy, parasites, and the hygiene hypothesis. Science (2002) 296(5567):490–494.
  • NGUYEN KB, WATFORD WT, SALOMON R et al.: Critical role for STAT4 activation by Type 1 interferons in the interferon-gamma response to viral infection. Science (2002) 297 (5589):2063–2066.
  • BOT A, RODRIGO E, WOLFE T, BOT S, VON HERRATH MG: Infection-triggered regulatory mechanisms over-ride the role of STAT 4 in control of the immune response to influenza virus antigens. Vim/. (2003) 77(10):5794–5800.
  • XING Z: Breach of IL-12 monopoly in the initiation of Type 1 immunity to intracellular infections: IL-12 is not required for host defense against viral infection. Cell. Ma Biol. (2001) 47(4):689–694.
  • DIEHL S, RINCON M: The two faces of IL-6 on Thl/Th2 differentiation. Ma Immunol (2002) 39(9):531–536.
  • KIDD P: Thl/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Ahern. Med.. Rev (2003) 8(3):223–246.
  • SZABO SJ, KIM ST, COSTA GL, ZHANG X, FATHMAN CG, GLIMCHER LH: A novel transcription factor, T-bet, directs Thl lineage commitment. Cell (2000) 100(6):655–669.
  • ••The new finding of the transcription factorT-bet which controls Thl immunity.
  • FARRAR JD, ASNAGLI H, MURPHY KM: T helper subset development: roles of instruction, selection, and transcription. I Clin. Invest. (2002) 109(4):431–435.
  • ZHENG W, FLAVELL RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 89(4):587–596.
  • SHIRAFUJI Y, MATSUURA H, SATO A, KANZAKI H, KATAYAMA H, ARATA J: Hyperimmunoglobin E syndrome: a sign of TH1/TH2 imbalance? Eur: Dermatol (1999) 9(2):129–131.
  • SASAKI S, TAKESHITA F, OKUDA K, ISHII N: Mycobacterium leprae and leprosy: a compendium. Microbial. Immunol (2001)45(11):729–736.
  • KAPLAN G, BRITTON WJ, HANCOCK GE et al.: The systemic influence of recombinant IL-2 on the manifestations of lepromatous leprosy. J. Exp. Med. (1991) 173(4):993–1006.
  • BARRAL-NETTO M, SANTOS S, SANTOS I et al.: Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy. Acta. Trop. (1999) 72(2):185–201.
  • HUBEL K, DALE DC, LILES WC: Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. Infect. Dis. (2002) 185(10):1490–1501. Epub 2002 Apr 19.
  • RODRIGUEZ FH, NELSON S, KOLLS JK: Cytokine therapeutics for infectious diseases. Can: Pharm. Des. (2000) 6(6):665–680.
  • LIESCHKE GJ, GRAIL D, HODGSON G et al.: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood (1994) 84(6):1737–1746.
  • DIRKSEN U, NISHINAKAMURA R, GRONECK P et al.: Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J. Clin. Invest. (1997) 100(9):2211–2217.
  • NISHINAKAMURA R, NAKAYAMA N, HIRABAYASHI Y et al.: Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunig, (1995) 2(3):211–222.
  • FRENCK RW, SARMAN G, HARPER TE, BUESCHER ES: The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus atoms. J. Infect. Dis. (1990) 162(1):109–114.
  • WANG J, ZGANIACZ A, XING Z: Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine (2002) 20(23-24):2887–2898.
  • CAIRO MS, PLUNKETT JM, MAUSS D,VAN DE VEN C: Seven-day administration of recombinant human granulocyte colony-stimulating factor to
  • •• newborn rats: modulation of neonatal neutrophilia, myelopoiesis, and group B Streptococcus sepsis. Blood (1990) 76(9):1788–1794.
  • ANGEL JB, HIGH K, RHAME F et al.: Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS. (2000) 14(4):387–395.
  • BANERJEA MC, SPEER CP: The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis. Semin. Neonatol (2002)7(4):335–349.
  • GALLIN JI, FARBER JM, HOLLAND SM, NUTMAN TB: Interferon-gamma in the management of infectious diseases. Ann. Intern. Med. (1995) 123(3):216–224.
  • GESSANI S, BELARDELLI F: IFN-gamma expression in macrophages and its possible biological significance. Cytokine Growth Factor Rev. (1998) 9(2):117–123.
  • WANG J, WAKEHAM J, HARKNESS R, XING Z: Macrophages are a significant source of Type 1 cytokines during mycobacterial infection. " Clin. Invest. (1999) 103(7):1023–1029.
  • NEWPORT MJ, HUXLEY CM, HUSTON S et al.: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. (1996) 335 (26):1941–1949.
  • JOUANGUY E, ALTARE F, LAMHAMEDI S et al.: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Eng.]Med. (1996) 335(26):1956–1961..
  • DORMAN SE, HOLLAND SM: Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection.Clin. Invest. (1998) 101(11):2364–2369.
  • FIESCHI C, CASANOVA JL: The role of interleukin-12 in human infectious diseases: only a faint signature. Ear: I Immunol (2003) 33(6):1461–1464.
  • ••Consideration of redundant role of IL-12in defence against infection other than mycobacteria and salmonella.
  • HUANG S, HENDRIKS W, ALTHAGE A et al.: Immune response in mice that lack the interferon-gamma receptor. Science (1993) 259(5102):1742–1745.
  • KAMIJO R, LE J, SHAPIRO D et al.: Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide.f Exp. Med. (1993) 178(4):1435–1440.
  • DECKERT-SCHLUTER M, RANG A, WEINER D et al.: Interferon-gamma receptor-deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Lab. Invest. (1996) 75(6):827–841.
  • DALTON DK, PITTS-MEEK S, KESHAV S, FIGARI IS, BRADLEY A, STEWART TA: Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science (1993) 259(5102):1739–1742.
  • GALLIN JI: Delineation of the phagocyte NADPH wddase through studies of chronic granulomatous diseases of childhood. bit. .1 Tissue React. (1993) 15(3):99–103.
  • VERCELLI D, JABARA HH, CUNNINGHAM-RUNDLES C: Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. .1. Clin. Invest. (1990) 85(5):1666–1671.
  • JEPPSON JD, JAFFE HS, HILL HR: Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyperimmunoglobulinemia E and recurrent infections.' Pediatr. (1991) 118 (3):383–387.
  • POYNARD T, YUEN ME RATZIU V, LAI CL: Viral hepatitis C. Lancet (2003) 362(9401):2095–2100.
  • YUEN MF, LAI CL: Treatment of chronic hepatitis B. Lancet Infect. Dis. (2001) 1(4):232–241.
  • ABDI K: IL-12: the role of p40 versus p75. Scand Immunol (2002) 56(1):1–11.
  • MURAILLE E, PAJAK B, URBAIN J, MOSER M, LEO 0: Role and regulation of IL-12 in the in vivo response to staphylococcal enterotoxin B. Int. Immunol (1999) 11(9):1403–1410.
  • COOPER AM, KIPNIS A, TURNER J, MAGRAM J, FERRANTE J, ORME IM: Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. .1. Immunol (2002) 168(3):1322–1327.
  • OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13(5):715–725.
  • ••It reports the finding of a new Type 1cytokine IL-23 composed of IL-12p40 and novel p19.
  • LANKFORD CS, FRUCHT DM: A unique role for IL-23 in promoting cellular immunity. I Leukoc. Biol. (2003) 73(1):49–56.
  • PFLANZ S, TIMANS JC, CHEUNG J et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity (2002) 16(6):779–790.
  • STANDIFORD TJ: Anti-inflammatory cytokines and cytokine antagonists. Carr. Pharm. Des. (2000) 6(6):633–649.
  • WAJANT H, PFIZENMAIER K, SCHEURICH P: Tumour necrosis factor signalling. Cell Death Differ. (2003) 10(1):45–65.
  • REMICK DG: Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Carr. Pharm. Des. (2003) 9 (1):75–82.
  • •History and prospects of cytokine therapy against bacterial sepsis.
  • DINARELLO CA: Anticytoldne therapeutics and infections. Vaccine (2003) 21 (Suppl. 2):524–34.
  • KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl. I Med. (2001) 345(15):1098–1104.
  • ZGANIACZ A, SANTOSUOSSO M, WANG J et al.: TNF-alpha is a critical negative regulator of Type 1 immune activation during intracellular bacterial infection. " Clin. Invest. (2004) 113(3):401–413.
  • •This paper reveals a new role by TNF in host defence and cautions the clinical use of the TNF inhibitors.
  • BALKWILL F: Cancer and the chemokine network. Nat. Rev. Cancer (2004) 4(7):540–550.
  • ALKHATIB G, COMBADIERE C, BRODER CC et al.: CC CKR5: a RANTES, MIP-lalpha, MIP-lbeta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272(5270):1955–1958.
  • ••This article illustrates that CCR5 is aprimary co-receptor for macrophage-tropic HIV.
  • DENG HK, UNUTMAZ D, KEWAL, RAMANI VN, LITTMAN DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (1997) 388(6639):296–300.
  • COCCHI F, DEVICO AL, GARZINO-DEMO A, ARYA SK, GALLO RC, LUSSO P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8' T cells. Science (1995) 270 (5243):1811–1815.
  • BLEUL CC, FARZAN M, CHOE H et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382(6594):829–833.
  • OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/ fusin and prevents infection by T cell line-adapted HIV-1. Nature (1996) 382(6594):833–835.
  • SHAHEEN F, COLLMAN RG: Co-receptor antagonists as HIV-1 entry inhibitors. Can: Opin. Infect. Dis. (2004) 17(1):7–16.
  • PHILPOTT SM: HIV-1 coreceptor usage, transmission, and disease progression. Curc HIV Res. (2003) 1(2):217–227.
  • KELDER W, MCARTHUR JC, NANCE-SPROSON T, MCCLERNON D, GRIFFIN DE: Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol (1998) 44(5):831–835.
  • GONZALEZ E, ROVIN BH, SEN L et al.: HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Nati Acad. Sci. USA (2002) 99(21):13795–13800. Epub 2002 Oct 08.
  • CINQUE P, VAGO L, MENGOZZI M et al.: Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. (1998) 12 (11):1327–1332.
  • XING Z: The hunt for new tuberculosis vaccines: antiTB immunity and rational design of vaccines. Carr: Pharm. Des.(2001) 7(11):1015–1037.
  • •An in-depth review of antituberculosis immunity and vaccine development.
  • MANTOVANI A, LOCATI M, VECCHI A, SOZZANI S, ALLAVENA P: Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol (2001) 22(6):328–336.
  • PIROFSKI LA, CASADEVALL A: Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol Rev (1998) 11(1):1–26.
  • BREWER JM, CONACHER M, HUNTER CA, MOHRS M, BROMBACHER F, ALEXANDER J: Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signalling. J. Immunol (1999) 163(12):6448–6454.
  • CRIBBS DH, GHOCHIKYAN A, VASILEVKO V et al.: Adjuvant-dependent modulation of Thl and Th2 responses to immunization with beta-amyloid.Int. Immunol (2003) 15(4):505–514.
  • CHEN L, WANG J, ZGANIACZ A, XING Z: Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. (2004) 72(1):238–246.
  • YOUNG S, O'DONNELL M, LOCKHART E et al.: Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol. (2002) 80(3):209–215.
  • WANG J, XING Z: Tuberculosis vaccines: the past, present and future. Expert Rev. Vaccines (2002) 1(3):341–354.
  • ULEVITCH RJ: Therapeutics targeting the innate immune system. Nat. Rev Immunol (2004) 4(7):512–520.
  • MARTIN GS, MANNINO DM, EATON S, MOSS M: Epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. (2003) 348 (16): 1546–1554.
  • WAAGE A, HALSTENSEN A, ESPEVIK T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 1(8529):355–357.
  • TRACEY KJ, BEUTLER B, LOWRY SF et al.: Shock and tissue injury induced by recombinant human cachectin. Science (1986) 234 (4775):470–474.
  • TRACEY KJ, FONG Y, HESSE DG et al.: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330(6149):662–664.
  • BEUTLER B, MILSARK IW, CERAMI AC: Passive immunization against cachectin/tumour necrosis factor protects mice from lethal effect of endotwdn. Science (1985) 229 (4716):869–871.
  • ••The first report on anti-TNF therapyagainst lethal effect of endotoxin.
  • MOHLER KM, TORRANCE DS, SMITH CA et al.: Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. Immunol (1993) 151(3):1548–1561.
  • ABRAHAM E, WUNDERINK R, SILVERMAN H et al.: Efficacy and safety of monoclonal antibody to human tumour necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. "AMA (1995) 273(12):934–941.
  • COHEN J, CARLET J: INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumour necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Grit. Care Med. (1996) 24(9):1431–1440.
  • ABRAHAM E, ANZUETO A, GUTIERREZ G et al.: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 351(9107):929–933.
  • REMICK DG, CALL DR, EBONG SJ et al.: Combination immunotherapy with soluble tumour necrosis factor receptors plus IL-1 receptor antagonist decreases sepsis mortality. Grit. Care Med. (2001) 29(3):473–481.
  • SANTOSUOSSO M, WANG J, XING Z In: Progress M Tuberculosis Research, Frank Columbus (Ed.), Nova Science Publishers, Inc., Hauppauge, NY. (2004) (In press).
  • XING Z, ZGANIACZ A, SANTOSUOSSO M: Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gammainduction. J. Leak. Biol. (2000) 68 (6):897–902.
  • FREIDAG BL, MELTON GB, COLLINS F et al.: CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M tuberculosis Infect. Immun. (2000) 68(5):2948–2953.
  • KOHNO K, KATAOKA J, OHTSUKI T et al.: IFN-gamma-inducing factor (TGIF) is a costimulatory factor on the activation of Thl but not Th2 cells and exerts its effect independently of IL-12. .1 Immunol (1997) 158(4):1541–1550.
  • DINARELLO CA, NOVICK D, PUREN AJ et al.: Overview of interleukin-18: more than an interferon-gamma inducing factor. J. Leak. Biol. (1998) 63(6):658–664.
  • HOSHINO T, KAWASE Y, OKAMOTO M et al.: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J. Immunol (2001) 166(12):7014–7018.
  • KEMBLE G, GREENBERG H: Novel generations of influenza vaccines. Vaccine (2003) 21(16):1789–1795.
  • VAN SLOOTEN ML, HAYON I, BABAI I et al.: Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. Biochim. Biophys. Acta. (2001) 1531(1-2):99–110.
  • ARULANANDAM BP, MITTLER JN, LEE WT, O'TOOLE M, METZGER DW: Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. Immunol (2000) 164(7):3698–3704.
  • BABAI I, SAMIRA S, BARENHOLZ Y, ZAKAY-RONES Z, KEDAR E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/ neuraminidase and IL-2 or GM-CSE I. Vaccine characterization and efficacy studies in mice. Vaccine (1999) 17 (9-10):1223–1238.
  • PAUKSEN K, LINDE A, HAMMARSTROM V et al.: Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis. (2000) 30(2):342–348.
  • BEN-YEHUDA A, JOSEPH A, BARENHOLZ Y et al.: Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine(INFLUSOME-VAC) in nursing-home residents. Vaccine (2003) 21 (23):3169–3178.
  • BEN-YEHUDA A, JOSEPH A, ZEIRA E et al.: Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. Med. Virol (2003) 69(4):560–567.
  • GOTCH FM, IMAMI N, HARDY G: Candidate vaccines for immunotherapy in HIV. HIV Med. (2001) 2(4):260–265.
  • WILSON JD, IMAMI N, WATKINS A et al.: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus Type 1 specificity equates with progression to disease. J. Infect. Dis. (2000) 182(3):792–798. Epub (2000) Aug 17.
  • APPAY V, NIXON DF, DONAHOE SM et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. (2000) 192(1):63–75.
  • MCNEIL AC, SHUPERT WL, IYASERE CA et al.: High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Nat! Acad. Sci. USA (2001) 98 (24):i3878–i3883.
  • ROSENBERG ES, BILLINGSLEY JM, CALIENDO AM et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 278(5342):1447–1450.
  • RINALDO C, HUANG XL, FAN ZF et al.: High levels of antihuman immunodeficiency virus Type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. Virol (1995) 69(9):5838–5842.
  • KOVACS JA, BASELER M, DEWAR RJ et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl. J. Med. (1995) 332(9):567–575.
  • KOVACS JA, VOGEL S, ALBERT JM et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl. J. Med. (1996) 335(18):1350–1356.
  • LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20(15):1964–1967.
  • •This review describes a new approach of therapeutic use of chemokines against HIV infection.
  • LIU R, PAXTON WA, CHOE S et al.: Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86(3):367–377.
  • POLO S, NARDESE V, DE SANTIS C et al.: Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Ear: Immunol (2000) 30(11):3190–3198.
  • NARDESE V, LONGHI R, POLO S et al.: Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat. Struct. Biol. (2001) 8(7):611–615.
  • YANG AG, BAI X, HUANG XF, YAO C, CHEN S: Phenotypic knockout of HIV Type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Nati Acad. Sci. USA (1997) 94(21):11567–11572.
  • GROLL AH, SHAH PM, MENTZEL C, SCHNEIDER M, JUST-NUEBLING G, HUEBNER K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. (1996) 33(1):23–32.
  • STEINBACH WJ, STEVENS DA: Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. (2003) 37 (Suppl. 3):S157–S187.
  • SCHAFFNER A, DOUGLAS H, BRAUDE A: Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergi//us. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. Gin. Invest. (1982) 69(3):617–631.
  • ROILIDES E, UHLIG K, VENZON D, PIZZO PA, WALSH TJ: Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. (1993) 61(4):1185–1193.
  • ROMANI L, MENCACCI A, GROHMANN U et al.: Neutralizing antibody to IL-4 induces systemic protection and T helper Type 1-associated immunity in murine candidiasis. .1. Exp. Med. (1992) 176(1):19–25.
  • MAYER P, SCHUTZE E, LAM C, KRICEK F, LIEHL E: Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. .1. Infect. Dis. (1991) 163(3):584–590.
  • BRUMMER E, MAQBOOL A, STEVENS DA: ha vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages. Leukoc. Biol. (2001) 70(6):868–872.
  • BODEY GP, ANAISSIE E, GUTTERMAN J, VADHAN-RAJ S: Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin. Infect. Dis. (1993) 17(4):705–707.
  • GONZALEZ CE, COURIEL DR, WALSH TJ: Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin. Infect. Dis. (1997) 24(2):192–196.
  • SAHIN B, PAYDAS S, COSAR E, BICAKCI K, HAZAR B: Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur. Clin. Microbial. Infect. Dis. (1996)15(11):866–869.

Websites

  • http://www.iddb.com/ The Investigational Drugs database, 01997–2004 Derwent Information Ltd.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.